Zealand Pharma Completes DKK 1.3 Billion Share Buyback Early, Repurchasing 4.4 Million Shares
Zealand Pharma said on Monday, October 5, 2026 that its share buyback program, launched May 7 at about DKK 1.3 billion (roughly $200 million), was completed ahead of its October 31 deadline after lead manager Danske Bank closed it once the full amount was reached. Zealand bought back 4,408,500 shares at an average price of DKK 294.88 and now holds 5,279,342 treasury shares, about 7.37% of its share capital. The Danish peptide company's lead obesity drug, the amylin analog petrelintide partnered with Roche, entered Phase 3 on September 22.